

EUROPEAN DIABETOLOGY

England & Wales · Charity number 1156725

Details

Status Registered

Legal form Charitable company

Company number [08652560](#)

Registered 2014-04-16

Register [View on the Charity Commission register](#)

Contact

Address LEARNING & RESEARCH BUILDING
Southmead Hospital
Westbury-On-Trym
Bristol
BS10 5NB

Phone 01174147886

Email european-diabetology@bristol.ac.uk

Activities

Objects: THE CHARITY'S OBJECTS ARE SPECIFICALLY RESTRICTED TO ADVANCE THE EDUCATION OF THE PUBLIC IN GENERAL (AND PARTICULARLY AMONG SCIENTISTS AND HEALTHCARE PROFESSIONALS) ON THE SUBJECT OF DIABETOLOGY, IN PARTICULAR BY (BUT NOT LIMITED TO) THE PROMOTION OF RESEARCH FOR THE PUBLIC BENEFIT IN ALL ASPECTS OF THAT SUBJECT AND TO PUBLISH THE USEFUL RESULTS.

Activities: The Charity's objectives are specifically restricted to advance the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology, in particular by (but not limited to) the promotion of research for the public benefit in all aspects of that subject and to publish the useful results.

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Germany
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-08-31	£768,833	£577,015	£1,741,824	0
2024-08-31	£579,424	£273,994	£1,514,893	0
2023-08-31	£702,711	£908,875	£1,170,415	0
2022-08-31	£644,149	£470,213	£1,407,623	0
2021-08-31	£611,516	£639,525	£1,217,203	0
2020-08-31	£908,487	£642,386	£1,238,545	0

Trustees

Name	Role	Appointed
Professor Ewan Pearson	Chair	2021-09-01
Dr Femke Rutters		2024-09-18
Emma Jane Doble		2025-09-01
Professor Bo Ahren		2020-07-17
Professor Maciej Malecki		2025-02-04
Professor Michele Solimena		2025-09-01
Professor Ruth Loos		2022-06-17

Accounts

Charity Registration No. 1156725

Company Registration No. 08652560 (England and Wales)

EUROPEAN DIABETOLOGY
REPORT AND UNAUDITED FINANCIAL
STATEMENTS
FOR THE YEAR ENDED
31 AUGUST 2025

EUROPEAN DIABETOLOGY

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees and Management Committee	Prof B Ahren Ms E Doble (appointed 1 September 2025) Prof R Loos Prof M Malecki (appointed 4 February 2025) Prof E Pearson Dr F Rutters (appointed 18 September 2024) Prof M Solimena (appointed 1 September 2025)
Secretary	Ms M L Preston
Charity number	1156725
Company number	08652560
Principal address	Learning & Research Building Southmead Hospital Westbury-On-Trym Bristol BS10 5NB
Registered office	RSM 2nd Floor One The Square Temple Quay Bristol BS1 6DG
Independent examiner	Kerry Gallagher FCA DChA RSM UK Tax and Accounting Limited Chartered Accountants Davidson House Reading Berkshire RG1 3EU
Bankers	Barclays Bank Plc 15 Queen Square Bristol BS1 4NP

EUROPEAN DIABETOLOGY

TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 AUGUST 2025

The Trustees present their report and financial statements for the year ended 31 August 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition - October 2019.

Objectives and activities

The Charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results. In this year, the Charity continued to support the European Association for the Study of Diabetes' (EASD) Early Career Academy with a grant, enabling 25 applicants to take a place on its new Early Career Mentorship programme. It also took an active role in the creation of Diabetologia's sister journal Metabologia and negotiating the contract with publisher Springer Nature, with the aim of best serving its authors and readership in view of the Charity's objects. The expanded scope of the new journal offers increased opportunity for the Charity to communicate about further fields and their relation to diabetology. In addition, they supported the IDS conference with a grant towards its Young Investigator Travel Awards aimed to motivate young scientists to send in abstracts.

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

The Trustees have also paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

Achievements and performance

The Charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal Diabetologia, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

Financial review

Total income for the financial year was £768,833 (2024: £579,424). Outgoings and other gains/losses for the same year were £541,902 (2024: £234,946) creating an annual surplus of £226,931 (2024: 344,478). Total funds carried forward into the new financial year are £1,741,824 (2024: £1,514,893).

Reserves policy

The Trustees examined the requirements for free reserves in November 2023 and agreed that, given the nature of the work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of six months' running costs of Diabetologia to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer Nature. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of Diabetologia. It also gives adequate working capital to support quality improvement in Diabetologia. Therefore, the Trustees have decided to earmark £450,000 to a separate designated fund for clarity within the financial statements. The reserves as of 31 August 2025 are £1,741,824 (2024: £1,514,893).

Investment policy

During the year, the Charity maintained a multi-asset fund with Schrodgers. As the Charity's investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

EUROPEAN DIABETOLOGY

TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT)(CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

Risk management

The Trustees consider the main risk to the future of the Charity to be the funding provided, without this the Charity would not be able to provide support for the publication of the journals Diabetologia and Metabologia. The Trustees have publishing agreements in place with Springer Nature to receive royalties annually and work closely with EASD and the journals' Editors-in-Chief to ensure the financial forecast is secured.

The Charity plans to continue supporting the activities of Diabetologia and also now Metabologia, and to fund new initiatives that serve to develop diabetes education in the scientific, medical and wider community as well as improve the quality of the journals' output and marketing, when finances permit.

Structure, governance and management

European Diabetology is a company limited by guarantee (Company Registration No. 08652560) with charitable status (Charity Registration No. 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014. The registered office is RSM, 2nd Floor, One The Square, Temple Quay, Bristol BS1 6DG.

The Trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof E Pearson (Chair)	
Prof F Rutters (Vice Chair)	(appointed 18 September 2024)
Prof B Ahren (Treasurer)	
Ms E Doble	(appointed 1 September 2025)
Prof K Gillespie	(resigned 26 February 2025)
Prof R Loos	
Prof M Malecki	(appointed 4 February 2025)
Ms S Tweddell	(resigned 16 November 2025)

The day-to-day management of the Charity is carried out by the Trustees, who are appointed by a resolution of the Trustees from a candidate, or candidates, nominated in writing by the European Association for the Study of Diabetes. The number of Trustees shall not be less than three but shall not be subject to any maximum. The Trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

Members' liability

Each member of the charitable company undertakes to contribute to the assets of the charitable company in the event of it being wound up while they are a member, or within one year after they cease to be a member, such amount as may be required, not exceeding £1, for the debts and liabilities contracted before they ceased to be a member.

Related party transactions

In its commitment to advance education regarding diabetes, European Diabetology is primarily supportive of the journals Diabetologia and Metabologia and their associated society, the European Association for the Study of Diabetes (EASD). This may be in the form of financial grants but also professional benevolence. EASD is the Charity's primary beneficiary and the Charity remains open to assisting its various outreach initiatives.

EUROPEAN DIABETOLOGY

TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT)(CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

The Trustees report was approved by the Board of Trustees.

Bo Ahren

.....

Prof B Ahren

Trustee

Dated: 26/05/26.....

EUROPEAN DIABETOLOGY

STATEMENT OF TRUSTEES RESPONSIBILITIES

FOR THE YEAR ENDED 31 AUGUST 2025

The Trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

EUROPEAN DIABETOLOGY

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report on the financial statements of the Charity for the year ended 31 August 2025, which are set out on pages 6 to 15.

Respective responsibilities of Trustees and examiner

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the financial statements present a 'true and fair view' and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act.

I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the applicable requirements concerning the form and content of financial statements set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the financial statements give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Kerry Gallagher

Kerry Gallagher FCA DChA

The Institute of Chartered Accountants in England and Wales

On behalf of RSM UK Tax and Accounting Limited

Chartered Accountants

Davidson House

Forbury Square

Reading

Berkshire

RG1 3EU

Dated: 26/05/26

EUROPEAN DIABETOLOGY

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 AUGUST 2025

		Unrestricted funds 2025 £	Unrestricted funds 2024 £
	Notes		
<u>Income from:</u>			
Charitable activities	2	728,645	554,331
Investments	3	40,188	25,093
Total income		<u>768,833</u>	<u>579,424</u>
<u>Expenditure on:</u>			
Charitable activities	4	<u>577,015</u>	<u>273,994</u>
Net income before gains/(losses)		191,818	305,430
Net gains on investments	9	44,644	39,818
Other losses	10	(9,531)	(770)
Net movement in funds		<u>226,931</u>	<u>344,478</u>
Total funds brought forward		<u>1,514,893</u>	<u>1,170,415</u>
Total funds carried forward		<u><u>1,741,824</u></u>	<u><u>1,514,893</u></u>

All income and expenditure derives from continuing activities and was unrestricted in the current and previous year.

EUROPEAN DIABETOLOGY

BALANCE SHEET

AS AT 31 AUGUST 2025

	Notes	2025 £	£	2024 £	£
Fixed assets					
Investments	11		629,123		563,166
Current assets					
Debtors	12	232,293		302	
Investments	13	300,000		-	
Cash at bank and in hand		813,639		1,118,284	
		1,345,932		1,118,586	
Creditors: amounts falling due within one year	14	(233,231)		(166,859)	
Net current assets			1,112,701		951,727
Total assets less current liabilities			1,741,824		1,514,893
Income funds					
Designated funds	16	450,000		450,000	
Unrestricted funds		1,291,824		1,064,893	
			1,741,824		1,514,893

The charitable company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006 (the Act) for the year ended 31 August 2025 and its members have not required the charitable company to have an audit of its financial statements for the period in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of the financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the officers on 26/05/26 and signed on their behalf by:

Bo Ahren

 Prof B Ahren
 Trustee

EUROPEAN DIABETOLOGY

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 AUGUST 2025

	Notes	2025 £	£	2024 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	18		(323,520)		177,649
Investing activities					
Interest received		18,875		7,985	
Net cash generated from investing activities			18,875		7,985
Net (decrease)/increase in cash and cash equivalents			(304,645)		185,634
Cash and cash equivalents at beginning of year			1,118,284		932,650
Cash and cash equivalents at end of year			813,639		1,118,284

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies

Charity information

European Diabetology (the Charity) is a private company limited by guarantee incorporated in England and Wales. The registered office is RSM, 2nd Floor, One The Square, Temple Quay, Bristol BS1 6DG. The Charity is registered in England and Wales by the Charity Commission (Charity Registration No. 1156725).

Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019).

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in Sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The Charity constitutes a public benefit entity as defined by FRS102.

The financial statements have been prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value. The principal accounting policies adopted are set out below.

Going concern

The Trustees have reviewed the expected cash outflows for the Charity against expected cash inflows and assets held for twelve months from the approval of these financial statements. The Trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these financial statements.

Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes. Designated funds are set aside by the Trustees to be spent on specific purposes at their own discretion. The designated funds currently in the financial statements relate to approximately six months' running costs of Diabetologia.

Income

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Investment income is accounted for in the accounting period in which it is receivable.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the Charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category.

Charitable expenditure comprises costs incurred by the Charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies (Continued)

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity and include independent examination fees and costs linked to the strategic management of the Charity.

Gains and losses

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities,

Investments

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

Financial instruments

The Charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade debtors and other debtors, cash on deposit and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest rate method.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Charity after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade creditors and other creditors are initially recognised at transaction price.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies (Continued)

Taxation

The Charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

Foreign exchange

Transactions in currencies other than Sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each balance sheet date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the balance sheet date. Gains and losses arising on translation are included in net income for the year.

2 Charitable activities

	2025 £	2024 £
Promotion of medical research	728,645	554,331

During the current and prior year, all income from charitable activities was received from markets outside the UK but within Europe.

3 Investments

	2025 £	2024 £
Dividend income	21,313	17,108
Interest receivable	18,875	7,985
	40,188	25,093

4 Charitable activities

	2025 £	2024 £
Promotion of medical research	528,059	259,372
Grant funding of activities (see note 5)	29,368	-
Share of support costs (see note 6)	15,469	12,372
Share of governance costs (see note 6)	4,119	2,250
	577,015	273,994
Analysis by fund		
Unrestricted funds - general	577,015	273,994

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

5 Grants payable

	2025 £	2024 £
Grants to institutions:		
EASD Academy Network Programme	21,028	-
KU Leven - 20th IDS Congress	8,340	-
	<u>29,368</u>	<u>-</u>

6 Support costs

	Support costs £	Governance costs £	2025 £	2024 £	Basis of allocation
Accountancy costs	11,103	-	11,103	8,033	
Travel and subsistence	2,381	-	2,381	1,698	
Computer costs	30	-	30	2,150	
Bank charges	744	-	744	491	
Office costs	9	-	9	-	
Insurance	678	-	678	-	
Other costs	524	-	524	-	
Legal and professional	-	748	748	-	Governance
Independent examination fees	-	3,371	3,371	2,250	Governance
	<u>15,469</u>	<u>4,119</u>	<u>19,588</u>	<u>14,622</u>	
Analysed between					
Charitable activities	<u>15,469</u>	<u>4,119</u>	<u>19,588</u>	<u>14,622</u>	

7 Trustees

The Trustees neither received nor waived any emoluments from the Charity during the year (2024: £Nil). Trustees received payments of £563 (2024: £1,698) in respect of travel costs reimbursed. The Trustees are considered to be key management personnel of the Charity.

8 Employees

European Diabetology has no employees. The personnel are employed by the University of Bristol, who recharge these costs to the Charity.

9 Net gains/(losses) on investments

	2025 £	2024 £
Unrealised gains on investments (note 11)	<u>44,644</u>	<u>39,818</u>

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

10 Other gains or losses

	2025 £	2024 £
Foreign exchange losses	9,531	770

11 Fixed asset investments

	2025 £	2024 £
Movement in fixed asset investments		
Market value brought forward	563,166	506,240
Additions	21,313	17,108
Valuation changes	44,644	39,818
Market value carried forward	629,123	563,166

The Charity holds investments in a multi-asset fund with Schroders.

12 Debtors

	2025 £	2024 £
Amounts falling due within one year:		
Trade debtors	103,864	-
Other debtors	1,514	136
Prepayments and accrued income	126,915	166
	232,293	302

13 Current asset investments

	2025 £	2024 £
Cash on deposit	300,000	-

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

14 Creditors: amounts falling due within one year

	2025 £	2024 £
Trade creditors	5,410	-
Accruals and deferred income	227,821	166,859
	<u>233,231</u>	<u>166,859</u>

Included in the above is £158,826 (2024: £159,515) of deferred income relating to the remaining amount due from the publishing agreement. All deferred income from 2024 has been released to the statement of financial activities in the current year.

15 Financial instruments

	2025 £	2024 £
Equity instruments measured at fair value through profit or loss	629,123	563,166

16 Movement in funds

The income funds of the Charity include the following designated funds which have been set aside out of unrestricted funds by the Trustees for specific purposes:

	Movement in funds				
	Balance at 1 September 2024 £	Incoming resources £	Resources expended £	Revaluations, gains and losses £	Balance at 31 August 2025 £
Unrestricted funds	1,064,893	768,833	(577,015)	35,113	1,291,824
Designated funds	450,000	-	-	-	450,000
	<u>1,514,893</u>	<u>768,833</u>	<u>(577,015)</u>	<u>35,113</u>	<u>1,741,824</u>

	Movement in funds				
	Balance at 1 September 2023 £	Incoming resources £	Resources expended £	Revaluations, gains and losses £	Balance at 31 August 2024 £
Unrestricted funds	720,415	579,424	(274,764)	39,818	1,064,893
Designated funds	450,000	-	-	-	450,000
	<u>1,170,415</u>	<u>579,424</u>	<u>(274,764)</u>	<u>39,818</u>	<u>1,514,893</u>

No restricted funds were received in the year.

The Trustees have decided to designate approximately six months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer Nature. The funds remain unrestricted and can be spent at the Trustees' discretion.

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

17 Analysis of net assets between funds

	2025 £	2024 £
Fund balances at 31 August 2025 are represented by:		
Investments	629,123	563,166
Current assets	1,345,932	1,118,586
Creditors: amounts falling due within 1 year	(233,231)	(166,858)
	<u>1,741,824</u>	<u>1,514,894</u>

18 Cash generated from operations

	2025 £	2024 £
Surplus for the year	226,931	344,478
Adjustments for:		
Investment income recognised in statement of financial activities	(40,188)	(25,093)
Fair value gains and losses on investments	(44,644)	(39,818)
Movements in working capital:		
Increase in cash on deposit	(300,000)	-
Increase in debtors	(231,991)	(8)
Increase/(decrease) in creditors	66,372	(101,910)
Cash (absorbed by)/generated from operations	<u>(323,520)</u>	<u>177,649</u>

19 Related party transactions

The University of Bristol are the employer of a Trustee of European Diabetology. Expenses of £527,499 were incurred in relation to the University of Bristol during the year (2024: £237,576). No interest is due if payment is received 30 days from the invoice date.

The following balance sheet items relate to amounts due to the University of Bristol:

	2025 £	2024 £
Accruals	61,872	-
Prepayments	123,745	-
	<u>185,617</u>	<u>-</u>

Accounts

European Diabetology

A COMPANY LIMITED BY GUARANTEE

TRUSTEES' REPORT
AND
UNAUDITED FINANCIAL STATEMENTS

For the year ended

31 August 2024

European Diabetology (A company limited by guarantee)

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES AND MANAGEMENT COMMITTEE

Prof E Pearson (Chair)
Prof R Loos
Prof B Ahren
S Tweddell
Prof K Gillespie
Dr F Rutters

SECRETARY
M L Preston

COMPANY NUMBER

08652560

REGISTERED CHARITY NUMBER

1156725

REGISTERED OFFICE

2ND Floor
1 The Square
Temple Quay
Bristol
BS1 6DG

PRINCIPAL OFFICE

Level 3
Learning & Research Building
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB

BANKERS

Barclays Bank Plc
15 Queen Square
Bristol
BS1 4NP

INDEPENDENT EXAMINER

RSM UK Tax and Accounting Limited
Chartered Accountants
Davidson House
Forbury Square
Reading
Berkshire
RG1 3EU

European Diabetology

(A company limited by guarantee)

TRUSTEES' REPORT

The Trustees present their report and unaudited financial statements for the year ended 31 August 2024.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) second edition – October 2019.

STRUCTURE, GOVERNANCE AND MANAGEMENT

European Diabetology is a company limited by guarantee (Company Registration No 08652560) with charitable status (Charity No 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014.

The Trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof E Pearson (Chair from May 2024)

Dr M Rutter (Resigned 1 May 2024 - Chair up to May 2024)

Dr R Loos

Prof B Ahren

S Tweddell

Prof K Gillespie

Dr F Rutters (Appointed 18 September 2024)

The day-to-day management of the charity is carried out by the Trustees, who are appointed by a resolution of the Trustees from a candidate, or candidates, nominated in writing by the European Association for the Study of Diabetes. The number of Trustees shall not be less than three but shall not be subject to any maximum. The Trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

MEMBERS' LIABILITY

Each member of the charitable company undertakes to contribute to the assets of the charitable company in the event of it being wound up while they are a member, or within one year after they cease to be a member, such amount as may be required, not exceeding £1, for the debts and liabilities contracted before they ceased to be a member.

RELATED PARTY TRANSACTIONS

In its commitment to advance the education regarding diabetes, European Diabetology is primarily supportive of the journal Diabetologia and its associated society, the European Association for the study of Diabetes (EASD). This may be in the form of financial grants but also professional benevolence. EASD is the charity's primary beneficiary and the charity remains open to assisting its various outreach initiatives.

OBJECTIVES AND ACTIVITIES

The charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results. In this year, the charity supported the EASD's Early Career Academy with a grant, enabling 20 applicants to take a place on its new Early Career Mentorship programme. It also took an active role in the ongoing negotiation of Diabetologia's contract with publisher Springer Nature and that of the planned launch of its sister journal, with the aim of best serving its staff, authors and readership in view of the charity object. In addition, they supported the IDS

European Diabetology

(A company limited by guarantee)

TRUSTEES' REPORT

conference with a grant towards its Young Investigator Travel Awards aimed to motivate young scientists to send in abstracts.

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

ACHIEVEMENTS AND PERFORMANCE

The charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal Diabetologia, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

FINANCIAL REVIEW

Total income for the financial year was £579,424 (2023: £702,711). Outgoings and other gains/losses for the same year were £234,946 (2023: £939,919) creating an annual surplus of £344,478 (2024: deficit £237,208). Total funds carried forward into the new financial year are £1,514,893 (2023: £1,170,415).

INVESTMENT POLICY

During the year, the charity maintained a multi-asset fund with Schroders. As the charity's investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

RESERVES

The Trustees examined the requirements for free reserves in November 2023 and agreed that, given the nature of the work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of 6 months' running costs of Diabetologia to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of Diabetologia. It also gives adequate working capital to support quality improvement in Diabetologia. Therefore, the Trustees have decided to earmark £450,000 to a separate designated fund for clarity within the financial statements.

Due to the renegotiation of the shared services agreement with University of Bristol with regard to Diabetologia and uncertainty related to overhead charges in addition to the ongoing discussions regarding the spin-off journal contract, expenditure this year was restrained to ensure the charity's financial position was future proofed.

The reserves as of 31 August 2024 are £1,514,893 (2023: £1,170,415).

PLANS FOR FUTURE PERIODS

The charity plans to continue supporting the activities of Diabetologia and to fund new initiatives that serve to develop diabetes education in the scientific, medical and wider community as well as improve the quality of the journal's output and marketing, when finances permit.

RISK MANAGEMENT

The Trustees consider the main risk to the future of the charity to be the funding provided, without this the charity would not be able to provide support for the publication of the journal Diabetologia. The Trustees have a publishing agreement in place with Springer Nature to receive royalties annually and work closely with EASD and the journal's Editor-in-Chief to ensure the financial forecast is secured.

European Diabetology
(A company limited by guarantee)
TRUSTEES' REPORT

THIRD PARTY INDEMNITY PROVISION FOR TRUSTEES

Qualifying third party indemnity provision is in place for the benefit of all Trustees of the charitable company.

SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.



On behalf of the board of Trustees

Prof E Pearson

TRUSTEE

Date: 22/04/25

European Diabetology

(A company limited by guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report to the Trustees on my examination of the financial statements of European Diabetology for the year ended 31 August 2024, which are set out on pages 7 to 16.

Responsibilities and basis of report

As the Trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's financial statements as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the financial statements present a 'true and fair view' and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

Since the company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities applicable to charities preparing their financial statement in accordance with the Financial Reporting Standard applicable in the UK and Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Kerry Gallagher

KERRY GALLAGHER FCA
The Institute of Chartered Accountants in England and Wales
Chartered Accountant

ON BEHALF OF RSM UK TAX AND ACCOUNTING LIMITED

Chartered Accountants
Davidson House
The Forbury
Reading
RG1 3EU

Date: 23 April 2024

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
(including an Income and Expenditure Account)
for the year ended 31 August 2024

		Unrestricted funds	Total funds	Total funds
		2024 £	2024 £	2023 £
INCOME FROM:				
	Note			
Charitable activities	2	554,331	554,331	682,931
Investments	3	17,108	17,108	19,780
Interest income	4	7,985	7,985	-
TOTAL		<u>579,424</u>	<u>579,424</u>	<u>702,711</u>
EXPENDITURE ON:				
Charitable activities	5	(273,994)	(273,994)	(909,255)
TOTAL		<u>(273,994)</u>	<u>(273,994)</u>	<u>(909,255)</u>
Net gain/(losses) on investments	7	39,818	39,818	(31,044)
NET INCOME/(EXPENDITURE)		<u>345,248</u>	<u>345,248</u>	<u>(237,588)</u>
Other recognised (losses)/gains		(770)	(770)	380
NET MOVEMENT IN FUNDS		<u>344,478</u>	<u>344,478</u>	<u>(237,208)</u>
RECONCILIATION OF FUNDS				
Total funds brought forward at 1 September		1,170,415	1,170,415	1,407,623
TOTAL FUNDS CARRIED FORWARD AT 31 AUGUST	14	<u>1,514,893</u>	<u>1,514,893</u>	<u>1,170,415</u>

All activities are classed as continuing and were unrestricted in the current and previous year.

European Diabetology

(A company limited by guarantee)

UNAUDITED BALANCE SHEET
as at 31 August 2024

	Note	2024 £	2023 £
FIXED ASSETS			
Investments	10	563,166	506,240
		<u>563,166</u>	<u>506,240</u>
CURRENT ASSETS			
Debtors	11	302	294
Cash at bank and in hand		1,118,284	932,650
		<u>1,118,586</u>	<u>932,944</u>
CREDITORS: Amounts falling due within one year	12	(166,859)	(268,769)
NET CURRENT ASSETS		<u>951,727</u>	<u>664,175</u>
NET ASSETS		<u>1,514,893</u>	<u>1,170,415</u>
FUNDS:			
Unrestricted funds	14	1,064,893	720,415
Designated funds	14	450,000	450,000
		<u>1,514,893</u>	<u>1,170,415</u>

For the year ended 31 August 2024, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to have an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 7 to 16 were approved and authorised for issue by the officers on and signed on their behalf by:



Prof E Pearson
TRUSTEE

22/04/25

European Diabetology

(A company limited by guarantee)

UNAUDITED STATEMENT OF CASHFLOWS

For the year ended 31 August 2024

	Notes	2024 £	2023 £
Cash provided by/(used in) operating activities	16	177,649	(386,792)
Cash flows from investing activities			
Interest from investments		7,985	-
Net cash provided by investing activities		<u>7,985</u>	<u>-</u>
Change in cash in the year		185,634	(386,792)
Cash at the beginning of the year		<u>932,650</u>	<u>1,319,442</u>
Cast at the end of the year		<u><u>1,118,284</u></u>	<u><u>932,650</u></u>

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2024

1 ACCOUNTING POLICIES

CHARITY INFORMATION

European Diabetology is a private company limited by guarantee and incorporated in England and Wales. The registered office is 2nd Floor, 1 The Square, Temple Quay, Bristol, BS1 6DG.

European Diabetology meets the definition of a public benefit entity under section 34 of FRS 102.

The principal objectives of the charity are detailed in the Trustees' report on page 2 of these financial statements.

The charity is a company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the entity.

ACCOUNTING CONVENTION

The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition – October 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006. The accounting policies as disclosed have been applied consistently throughout the current and preceding year.

The accounts are prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value.

The financial statements presented in sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

GOING CONCERN

The trustees have reviewed the expected cash outflows for the charity against expected cash inflows and assets held for 12 months from the approval of these financial statements. The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these accounts.

FUND ACCOUNTING

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been restricted for other purposes. Designated funds are set aside by the trustees to be spent on specific purposes as its own discretion. The designated funds currently in the financial statements relate to approximately 6 months' running costs of Diabetologia.

INCOME

Income from charitable activities is recognised when the charity is entitled to the income, it is probable that the income will be received, and the amount of income can be measured reliably.

Investment income is accounted for in the accounting period in which it is receivable.

1 ACCOUNTING POLICIES (CONTINUED)

EXPENDITURE

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Charitable expenditure comprises costs incurred by the charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include independent examination fees and costs linked to the strategic management of the charity.

GAINS AND LOSSES

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the statement of financial activities.

INVESTMENTS

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

FINANCIAL INSTRUMENTS

As the charity only has basic financial instruments, it has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102, to all of its financial instruments.

Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other debtors and cash and bank balances, are measured at transaction price including transaction costs.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2024

1 ACCOUNTING POLICIES (CONTINUED)

Basic financial liabilities

Basic financial liabilities, including accruals are recognised at transaction price.

TAXATION

The charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

FOREIGN CURRENCIES

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the net income for the year.

2 INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds	Total funds	Total funds
	2024 £	2024 £	2023 £
Promotion of medical research	554,331	554,331	682,931
	=====	=====	=====

During the current and prior year, all the income from charitable activities was received from markets outside the UK but within Europe.

3 INCOME FROM INVESTMENTS

	Unrestricted funds	Total funds	Total funds
	2024 £	2024 £	2023 £
Dividend income	17,108	17,108	19,780
	=====	=====	=====

4 OTHER INTEREST RECEIVED

	Unrestricted funds	Total funds	Total funds
	2024 £	2024 £	2023 £
Interest income	7,985	7,985	-
	=====	=====	=====

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2024

5 ANALYSIS OF CHARITABLE EXPENDITURE

	Unrestricted funds Activities undertaken directly	Unrestricted funds Support costs (Note 6)	Total funds	Total funds
	2024 £	2024 £	2024 £	2023 £
Promotion of medical research	259,372	14,622	273,994	909,255
	<u>259,372</u>	<u>14,622</u>	<u>273,994</u>	<u>909,255</u>

The promotion of medical research costs in the year ended 31 August 2023 included £422,358 of costs relating to the year ended 31 August 2022 which had not been reflected in the financial statements for that year.

6 ALLOCATION OF SUPPORT AND GOVERNANCE COSTS

	Support costs	Governance costs	Total	Total
	2024 £	2024 £	2024 £	2023 £
Accountancy costs	8,033	-	8,033	8,108
Travel and subs hotel costs	1,698	-	1,698	-
Computer costs	2,150	-	2,150	-
Bank charges	491	-	491	748
Independent examination fees	-	2,250	2,250	2,150
	<u>12,372</u>	<u>2,250</u>	<u>14,622</u>	<u>11,006</u>

7 RECOGNISED GAINS/(LOSSES)

	Unrestricted funds	Total funds	Total funds
	2024 £	2024 £	2023 £
Unrealised gains/(losses) on investments (note 10)	39,818	39,818	(31,044)
	<u>39,818</u>	<u>39,818</u>	<u>(31,044)</u>

8 TRUSTEES

The Trustees neither received nor waived any emoluments from the charity during the year (2023: £nil). Trustees received payments of £1,698 (2023: nil) in respect of travel costs reimbursed. The Trustees are considered to be the key management personnel of the charity.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2024

9 EMPLOYEES

European Diabetology has no employees. The personnel are employed by The University of Bristol, who recharge these costs to the charity.

10 INVESTMENTS

	2024 £	2023 £
Valuation at 1 September	506,240	517,504
Additions	17,108	19,780
Unrealised gain/(loss) on investments	39,818	(31,044)
Valuation at 31 August	<u>563,166</u>	<u>506,240</u>

The charity holds investments in a multi-asset fund with Schroders.

11 DEBTORS

	2024 £	2023 £
Prepayments	166	158
Other debtors	136	136
	<u>302</u>	<u>294</u>

12 CREDITORS: Amounts falling due within one year

	2024 £	2023 £
Accruals and deferred income	166,859	268,769
	<u>166,859</u>	<u>268,769</u>

Included in the above is £159,515 (2023: £235,300) of deferred income. This is in relation to the remaining annual amount due from the publishing agreement. All deferred income from 2023 has been released to the statement of financial activities in the current year.

13 FINANCIAL INSTRUMENTS

	2024 £	2023 £
Equity instruments measured at fair value	<u>563,166</u>	<u>506,240</u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2024

14 MOVEMENTS IN FUNDS

	At 1 September 2023 £	Income £	Expenditure £	Net gains/ (losses) on investments £	At 31 August 2024 £
Unrestricted funds	720,415	579,424	(274,764)	39,818	1,064,893
Designated funds	450,000	-	-	-	450,000
	<u>1,170,415</u>	<u>579,424</u>	<u>(274,764)</u>	<u>39,818</u>	<u>1,514,893</u>
	At 1 September 2022 £	Income £	Expenditure £	Net gains/ (losses) on investments £	At 31 August 2023 £
Unrestricted funds	957,623	702,711	(908,875)	(31,044)	720,415
Designated funds	450,000	-	-	-	450,000
	<u>1,407,623</u>	<u>702,711</u>	<u>(908,875)</u>	<u>(31,044)</u>	<u>1,170,415</u>

No restricted funds were received in the year.

The Trustees have decided to designate approximately 6 months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. The funds remain unrestricted and can be spent at the Trustees' discretion.

15 ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Total Unrestricted Funds	Total Unrestricted Funds
	Year ended 31 August 2024 £	Year ended 31 August 2023 £
Fund balances at 31 August are represented by:		
Fixed assets	563,166	506,240
Current assets	1,118,586	932,944
Creditors: amounts falling due within one year	(166,858)	(268,769)
	<u>1,514,893</u>	<u>1,170,415</u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2024

16 RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASHFLOW FROM OPERATING ACTIVITIES

	2024	2023
	£	£
Net movement in funds	344,478	(237,208)
(Gain)/loss on investments	(39,818)	31,044
Dividends from investments	(17,108)	(19,780)
Interest income	(7,985)	-
(Increase)/decrease in debtors	(8)	35
Decrease in creditors	(101,910)	(160,883)
Net cash provided by/(used in) operating activities	<u>177,649</u>	<u>(386,792)</u>

17 ANALYSIS OF CHANGES IN NET FUNDS

	At 31 August 2023	Cash flows £	At 31 August 2024
	£		£
Cash at bank and in hand	932,650	185,635	1,118,285
	<u>932,650</u>	<u>185,635</u>	<u>1,118,285</u>

18 RELATED PARTIES

The University of Bristol are the employer of some of the trustees of European Diabetology. Expenses of £237,576 were incurred in relation to the University of Bristol during the year (2023: £898,075). No interest is due if payment is received 30 days from the invoice date. The following balance sheet items relate to amounts due to/ from the University of Bristol.

	2024	2023
	£	£
Accruals	-	26,397

Accounts

European Diabetology
A COMPANY LIMITED BY GUARANTEE
TRUSTEES' REPORT
AND
UNAUDITED FINANCIAL STATEMENTS
For the year ended
31 August 2023

European Diabetology

(A company limited by guarantee)

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES AND MANAGEMENT COMMITTEE

Prof M K Rutter (Chair)
Dr R Loos
Prof E Pearson
Prof B Ahren
S Tweddell
Prof K Gillespie

SECRETARY
M L Harris

COMPANY NUMBER

08652560

REGISTERED CHARITY NUMBER

1156725

REGISTERED OFFICE

2ND Floor
1 The Square
Temple Quay
Bristol
BS1 6DG

PRINCIPAL OFFICE

Level 3
Learning & Research Building
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB

BANKERS

Barclays Bank Plc
15 Queen Square
Bristol
BS1 4NP

INDEPENDENT EXAMINER

RSM UK Tax and Accounting Limited
Chartered Accountants
Davidson House
Forbury Square
Reading
Berkshire
RG1 3EU

European Diabetology

(A company limited by guarantee)

TRUSTEES' REPORT

The Trustees present their report and unaudited financial statements for the year ended 31 August 2023.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) second edition – October 2019.

STRUCTURE, GOVERNANCE AND MANAGEMENT

European Diabetology is a company limited by guarantee (Company Registration No 08652560) with charitable status (Charity No 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014.

The Trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof M K Rutter
Dr R Loos
Prof E Pearson
Prof B Ahren
S Tweddell
Prof K Gillespie

The day-to-day management of the charity is carried out by the Trustees, who are appointed by a resolution of the Trustees from a candidate, or candidates, nominated in writing by the European Association for the Study of Diabetes. The number of Trustees shall not be less than three but shall not be subject to any maximum. The Trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

MEMBERS' LIABILITY

Each member of the charitable company undertakes to contribute to the assets of the charitable company in the event of it being wound up while they are a member, or within one year after they cease to be a member, such amount as may be required, not exceeding £1, for the debts and liabilities contracted before they ceased to be a member.

RELATED PARTY TRANSACTIONS

In its commitment to advance the education regarding diabetes, European Diabetology is primarily supportive of the journal Diabetologia and its associated society, the European Association for the study of Diabetes (EASD). This may be in the form of financial grants but also professional benevolence. EASD is the charity's primary beneficiary and the charity remains open to assisting its various outreach initiatives.

OBJECTIVES AND ACTIVITIES

The charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results. In this year, the charity supported the EASD's Young Academy with a grant, enabling 20 applicants to take a place on its new Early Career Mentorship programme. It also took an active role in the ongoing negotiation of Diabetologia's contract with publisher Springer Nature, with the aim of best serving its staff, authors and readership in view of the charity object.

European Diabetology

(A company limited by guarantee)

TRUSTEES' REPORT

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

ACHIEVEMENTS AND PERFORMANCE

The charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal *Diabetologia* and the website *Diapedia*, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

FINANCIAL REVIEW

Total income for the financial year was £702,711 (2022: £644,149). Outgoings and other gains/losses for the same year were £939,919 (2022: £453,729) creating an annual deficit of £237,208 (2022: surplus £190,420). Total funds carried forward into the new financial year are £1,170,415 (2022: £1,407,623).

INVESTMENT POLICY

During the year, the charity maintained a multi-asset fund with Schroders. As the charity's investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

RESERVES

The Trustees examined the requirements for free reserves in November 2023 and agreed that, given the nature of the work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of 6 months' running costs of *Diabetologia* to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of *Diabetologia*. It also gives adequate working capital to support quality improvement in *Diabetologia*. Therefore, the Trustees have decided to earmark £450,000 to a separate designated fund for clarity within the financial statements. The reserves as of 31 August 2023 are £1,170,415 (2022: £1,407,623).

PLANS FOR FUTURE PERIODS

The charity plans to continue supporting the activities of *Diabetologia* and to fund new initiatives that serve to develop diabetes education in the scientific, medical and wider community as well as improve the quality of the journal's output and marketing, when finances permit.

RISK MANAGEMENT

The Trustees consider the main risk to the future of the charity to be the funding provided, without this the charity would not be able to provide support for the publication of the journal *Diabetologia*. The Trustees have a publishing agreement in place with Springer Nature to receive royalties annually and work closely with EASD and the journal's Editor-in-Chief to ensure the financial forecast is secured.

THIRD PARTY INDEMNITY PROVISION FOR TRUSTEES

Qualifying third party indemnity provision is in place for the benefit of all Trustees of the charitable company.

European Diabetology
(A company limited by guarantee)
TRUSTEES' REPORT

SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

On behalf of the board of Trustees

Prof M K Rutter

TRUSTEE

Date:



Bo Ahren

May 22, 2024

European Diabetology

(A company limited by guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report to the Trustees on my examination of the financial statements of European Diabetology for the year ended 31 August 2023, which are set out on pages 7 to 16.

Responsibilities and basis of report

As the Trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's financial statements as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the financial statements present a 'true and fair view' and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

Since the company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities applicable to charities preparing their financial statement in accordance with the Financial Reporting Standard applicable in the UK and Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Kerry Gallagher

KERRY GALLAGHER FCA
The Institute of Chartered Accountants in England and Wales
Chartered Accountant

ON BEHALF OF RSM UK TAX AND ACCOUNTING LIMITED

Chartered Accountants
Davidson House
The Forbury
Reading
RG1 3EU

Date: 23/05/24

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
(including an Income and Expenditure Account)
for the year ended 31 August 2023

		Unrestricted funds	Total funds	Total funds
		2023 £	2023 £	2022 £
INCOME FROM:				
	Note			
Charitable activities	2	682,931	682,931	625,401
Investments	3	19,780	19,780	18,748
TOTAL		<u>702,711</u>	<u>702,711</u>	<u>644,149</u>
EXPENDITURE ON:				
Charitable activities	4	(908,875)	(908,875)	(445,128)
TOTAL		<u>(908,875)</u>	<u>(909,255)</u>	<u>(445,128)</u>
Net losses on investments	6	(31,044)	(31,044)	(8,601)
NET (EXPENDITURE)/INCOME AND NET MOVEMENT IN FUNDS		<u>(237,208)</u>	<u>(237,208)</u>	<u>190,420</u>
RECONCILIATION OF FUNDS				
Total funds brought forward at 1 September		1,407,623	1,407,623	1,217,203
TOTAL FUNDS CARRIED FORWARD AT 31 AUGUST	13	<u>1,170,415</u>	<u>1,170,415</u>	<u>1,407,623</u>

All activities are classed as continuing and were unrestricted in the current and previous year.

European Diabetology
(A company limited by guarantee)
UNAUDITED BALANCE SHEET
as at 31 August 2023

	Note	2023 £	2022 £
FIXED ASSETS			
Investments	9	506,240	517,504
		<u>506,240</u>	<u>517,504</u>
CURRENT ASSETS			
Debtors	10	294	329
Cash at bank and in hand		932,650	1,319,442
		<u>932,944</u>	<u>1,319,771</u>
CREDITORS:			
Amounts falling due within one year	11	(268,769)	(429,652)
NET CURRENT ASSETS		<u>664,175</u>	<u>890,119</u>
NET ASSETS		<u><u>1,170,415</u></u>	<u><u>1,407,623</u></u>
FUNDS:			
Unrestricted funds	13	720,415	957,623
Designated funds	13	450,000	450,000
		<u><u>1,170,415</u></u>	<u><u>1,407,623</u></u>

For the year ended 31 August 2023, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to have an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 7 to 16 were approved and authorised for issue by the officers on and signed on their behalf by:



 Prof M K Rutter
 TRUSTEE


 Bo Ahren

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF CASHFLOWS
For the year ended 31 August 2023

	Notes	2023 £	2022 £
Cash (used in)/provided by operating activities	15	(386,792)	444,539
Change in cash in the year		(386,792)	444,539
Total cash brought forward		<u>1,319,442</u>	<u>874,903</u>
Total cash carried forward		<u><u>932,650</u></u>	<u><u>1,319,442</u></u>

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

for the year ending 31 August 2023

1 ACCOUNTING POLICIES

CHARITY INFORMATION

European Diabetology is a private company limited by guarantee and incorporated in England and Wales. The registered office is 2nd Floor, 1 The Square, Temple Quay, Bristol, BS1 6DG.

European Diabetology meets the definition of a public benefit entity under section 34 of FRS 102.

The principal objectives of the charity are detailed in the Trustees' report on page 2 of these financial statements.

The charity is a company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the entity.

ACCOUNTING CONVENTION

The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition – October 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006. The accounting policies as disclosed have been applied consistently throughout the current and preceding year.

The accounts are prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value.

The financial statements presented in sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

GOING CONCERN

The trustees have reviewed the expected cash outflows for the charity against expected cash inflows and assets held for 12 months from the approval of these financial statements. The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these accounts.

FUND ACCOUNTING

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been restricted for other purposes. Designated funds are set aside by the trustees to be spent on specific purposes as its own discretion. The designated funds currently in the financial statements relate to approximately 6 months' running costs of Diabetologia.

INCOME

Income from charitable activities is recognised when the charity is entitled to the income, it is probable that the income will be received, and the amount of income can be measured reliably.

Investment income is accounted for in the accounting period in which it is receivable.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023

1 ACCOUNTING POLICIES (CONTINUED)

EXPENDITURE

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Charitable expenditure comprises costs incurred by the charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include independent examination fees and costs linked to the strategic management of the charity.

GAINS AND LOSSES

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the statement of financial activities.

INVESTMENTS

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

FINANCIAL INSTRUMENTS

As the charity only has basic financial instruments, it has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102, to all of its financial instruments.

Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other debtors and cash and bank balances, are measured at transaction price including transaction costs.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023

1 ACCOUNTING POLICIES (CONTINUED)

Basic financial liabilities

Basic financial liabilities, including accruals are recognised at transaction price.

TAXATION

The charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

FOREIGN CURRENCIES

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the net income for the year.

2 INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds	Total funds	Total funds
	2023 £	2023 £	2022 £
Promotion of medical research	682,931	682,931	625,401
	<u> </u>	<u> </u>	<u> </u>

During the current and prior year, all the income from charitable activities was received from markets outside the UK but within Europe.

3 INCOME FROM INVESTMENTS

	Unrestricted funds	Total funds	Total funds
	2023 £	2023 £	2022 £
Dividend income	19,780	19,780	18,748
	<u> </u>	<u> </u>	<u> </u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023

4 ANALYSIS OF CHARITABLE EXPENDITURE

	Unrestricted funds Activities undertaken directly	Unrestricted funds Support costs (Note 5)	Total funds	Total funds
	2023 £	2023 £	2023 £	2022 £
Promotion of medical research	897,869	11,006	908,875	445,128
	<u>897,869</u>	<u>11,006</u>	<u>908,875</u>	<u>445,128</u>

The promotion of medical research costs in the year includes £422,358 of costs relating to the year ended 31 August 2022 which have not been reflected in the financial statements for that year.

5 ALLOCATION OF SUPPORT AND GOVERNANCE COSTS

	Support costs	Governance costs	Total	Total
	2023 £	2023 £	2023 £	2022 £
Accountancy costs	8,108	-	8,108	8,855
Bank charges	748	-	748	16
Independent examination fees	-	2,150	2,150	1,280
	<u>8,856</u>	<u>2,150</u>	<u>11,006</u>	<u>10,151</u>

6 RECOGNISED GAINS/(LOSSES)

	Unrestricted funds	Total funds	Total funds
	2023 £	2023 £	2022 £
Unrealised gains/(losses) on investments (note 9)	(31,044)	(31,044)	(8,601)
	<u>(31,044)</u>	<u>(31,044)</u>	<u>(8,601)</u>

7 TRUSTEES

The Trustees neither received nor waived any emoluments from the charity during the year (2022: £nil). No Trustees received payments (2022: nil) in respect of travel costs reimbursed. The Trustees are considered to be the key management personnel of the charity.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023

8 EMPLOYEES

European Diabetology has no employees. The personnel are employed by The University of Bristol, who recharge these costs to the charity.

9 INVESTMENTS

	2023 £	2022 £
Valuation at 1 September	517,504	507,357
Additions	19,780	18,748
Unrealised loss on investments	(31,044)	(8,601)
Valuation at 31 August	<u>506,240</u>	<u>517,504</u>

The charity holds investments in a multi-asset fund with Schroders.

10 DEBTORS

	2023 £	2022 £
Prepayments	158	210
Other debtors	136	119
	<u>294</u>	<u>329</u>

11 CREDITORS: Amounts falling due within one year

	2023 £	2022 £
Accruals and deferred income	268,769	429,652
	<u>268,769</u>	<u>429,652</u>

Included in the above is £235,300 (2022: £211,179) of deferred income. This is in relation to the remaining annual amount due from the publishing agreement. All deferred income from 2022 has been released to the statement of financial activities in the current year.

12 FINANCIAL INSTRUMENTS

	2023 £	2022 £
Equity instruments measured at fair value	<u>506,240</u>	<u>517,504</u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023

13 MOVEMENTS IN FUNDS

	At 1 September 2022 £	Income £	Expenditure £	Net gains/ (losses) on investments £	At 31 August 2023 £
Unrestricted funds	957,623	702,711	(908,875)	(31,044)	720,415
Designated funds	450,000	-	-	-	450,000
	<u>1,407,623</u>	<u>702,711</u>	<u>(908,875)</u>	<u>(31,044)</u>	<u>1,170,415</u>
	At 1 September 2021 £	Income £	Expenditure £	Net gains/ (losses) on investments £	At 31 August 2022 £
Unrestricted funds	767,203	644,149	(448,128)	(8,601)	957,623
Designated funds	450,000	-	-	-	450,000
	<u>1,217,203</u>	<u>644,149</u>	<u>(448,128)</u>	<u>(8,601)</u>	<u>1,407,623</u>

No restricted funds were received in the year.

The Trustees have decided to designate approximately 6 months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. The funds remain unrestricted and can be spent at the Trustees' discretion.

14 ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Total Unrestricted Funds	Total Unrestricted Funds
	Year ended 31 August 2023 £	Year ended 31 August 2022 £
Fund balances at 31 August are represented by:		
Fixed assets	506,240	517,504
Current assets	932,944	1,319,771
Creditors: amounts falling due within one year	(268,769)	(429,652)
	<u>1,170,415</u>	<u>1,407,623</u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023

15 RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASHFLOW FROM OPERATING ACTIVITIES

	2023	2022
	£	£
Net (expenditure)/income	(237,208)	190,420
Loss on investments	31,044	8,601
Dividends from investments	(19,780)	(18,748)
Decrease in debtors	35	106,171
(Decrease)/increase in creditors	(160,883)	158,095
Net cash (used in)/provided by operating activities	<u>(386,792)</u>	<u>444,539</u>

16 ANALYSIS OF CHANGES IN NET FUNDS

	At 31 August 2022	Cash flows	At 31 August 2023
	£	£	£
Cash at bank and in hand	1,319,442	(386,792)	932,650
	<u>1,319,442</u>	<u>(386,792)</u>	<u>932,650</u>

17 RELATED PARTIES

The University of Bristol are the employer of some of the trustees of European Diabetology. Expenses of £898,075 were incurred in relation to the University of Bristol during the year (2022: £460,062). No interest is due if payment is received 30 days from the invoice date. The following balance sheet items relate to amounts due to/ from the University of Bristol.

	2023	2022
	£	£
Accruals	<u>26,397</u>	<u>211,179</u>

Accounts

European Diabetology

A COMPANY LIMITED BY GUARANTEE

TRUSTEES' REPORT AND UNAUDITED FINANCIAL STATEMENTS

For the year ended

31 August 2022

European Diabetology

(A company limited by guarantee)

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES AND MANAGEMENT COMMITTEE

Prof M K Rutter
Dr R Loos
Prof E Pearson
Pro B Ahren
S Tweddell
Dr K Gillespie

SECRETARY

M L Harris

COMPANY NUMBER

08652560

REGISTERED CHARITY NUMBER

1156725

REGISTERED OFFICE

2ND Floor
1 The Square
Temple Quay
Bristol
B1 6DG

PRINCIPAL OFFICE

Level 3
Learning & Research Building
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB

BANKERS

Barclays Bank Plc
15 Queen Square
Bristol
BS1 4NP

INDEPENDENT EXAMINER

Chartered Accountants
Davidson House
The Forbury
Reading
RG1 3EU

The Trustees present their report and unaudited financial statements for the year ended 31 August 2022.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) second edition – October 2019.

STRUCTURE, GOVERNANCE AND MANAGEMENT

European Diabetology is a company limited by guarantee (Company Registration No 08652560) with charitable status (Charity No 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014.

The Trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof M K Rutter	
Dr R Loos	(Appointed 17 June 2022)
Prof E Pearson	(Appointed 1 September 2021)
Pro B Ahren	
S Tweddell	
Dr K Gillespie	
Prof M Bluher	(Resigned 30 April 2022)
Prof F Gribble	(Resigned 30 April 2022)

The day to day management of the charity is carried out by the Trustees, who are appointed by a resolution of the Trustees from a candidate or candidates nominated in writing by the European Association for the Study of Diabetes. The number of Trustees shall not be less than three but shall not be subject to any maximum. The Trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

OBJECTIVES AND ACTIVITIES

The charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results.

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

ACHIEVEMENTS AND PERFORMANCE

The charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal Diabetologia and the website Diapedia, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

FINANCIAL REVIEW

Total income for the financial year was £660,239 (2021: £611,516). Outgoings and other gains/losses for the same year were £448,436 (2021: £632,858) creating an annual surplus of £211,803 (2021: deficit £21,342). Total funds carried forward into the new financial year are £1,429,006 (2021: £1,217,203).

INVESTMENT POLICY

During the year, the charity maintained a multi-asset fund with Schroders. As the charity's investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

RESERVES

The Trustees examined the requirements for free reserves in November 2016 and agreed that, given the nature of our work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of 6 months' running costs of Diabetologia to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of Diabetologia as a result of ongoing negotiations and allows the charity to fund Diapedia for a further 12 months if this is the decision of the Trustees based on the review agreed at the meeting of Trustees on 18 November 2019. It also gives adequate working capital to support quality improvement in Diabetologia. The Trustees have decided to earmark these funds to a separate designated fund for clarity within the financial statements. The reserves as of 31 August 2022 are £1,429,006 (2021: £1,217,203).

PLANS FOR FUTURE PERIODS

The charity plans to continue supporting the activities of Diabetologia and to fund quality improvement activities when funds permit.

RISK MANAGEMENT

The Trustees consider the main risk to the future of the charity to be the funding provided, without this the charity would not be able to provide support for the publication of the journal Diabetologia and the website Diapedia. The Trustees have a publishing agreement in place with Springer for this funding and work closely with the funding committee to ensure this future funding is secured.

SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Martin Rutter

On behalf of the board of Trustees

Prof M K Rutter

TRUSTEE

Date: 27/01/23

European Diabetology

(A company limited by guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Trustees confirm they have complied with the duty in the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit. When reviewing the aims and objectives of the charitable company and in planning its future activities the Trustees refer to the guidance and consider, in particular, how planned activities will contribute to the aims and objectives they have set.

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report to the Trustees on my examination of the accounts of European Diabetology for the year ended 31 August 2022, which are set out on pages 6 to 16.

Responsibilities and basis of report

As the Trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the accounts present a 'true and fair view' and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

Since the company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Kerry Gallagher

KERRY GALLAGHER FCA
The Institute of Chartered Accountants in England and Wales
Chartered Accountant

ON BEHALF OF RSM UK TAX AND ACCOUNTING LIMITED

Chartered Accountants
Davidson House
The Forbury
Reading
RG1 3EU

Date: 27/01/23

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
(including an Income and Expenditure Account)
for the year ended 31 August 2022

		Unrestricted funds	Total funds	Total funds
		Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2021 £
INCOME FROM:				
	Note			
Charitable activities	2	625,401	625,401	594,055
Investments		18,748	18,748	17,461
TOTAL		<u>644,149</u>	<u>644,149</u>	<u>611,516</u>
EXPENDITURE ON:				
Charitable activities	3	(470,213)	(470,213)	(639,525)
TOTAL		<u>(470,213)</u>	<u>(470,213)</u>	<u>(639,525)</u>
Net (losses)/gains on investments	5	(8,601)	(8,601)	37,994
NET INCOME		<u>165,335</u>	<u>165,335</u>	<u>9,985</u>
Other recognised gains/(losses)	5	25,085	25,085	(31,327)
NET MOVEMENT IN FUNDS		<u>190,420</u>	<u>190,420</u>	<u>(21,342)</u>
RECONCILIATION OF FUNDS				
Total funds brought forward at 1 September		1,217,203	1,217,203	1,238,545
TOTAL FUNDS CARRIED FORWARD AT 31 AUGUST		<u>1,407,623</u>	<u>1,407,623</u>	<u>1,217,203</u>

All activities are classed as continuing and were unrestricted in the current and previous year.

European Diabetology

(A company limited by guarantee)

UNAUDITED BALANCE SHEET
as at 31 August 2022

	Note	2022 £	2021 £
FIXED ASSETS			
Investments	8	517,504	507,357
		<u>517,504</u>	<u>507,357</u>
CURRENT ASSETS			
Debtors	9	329	106,500
Cash at bank and in hand		1,319,442	874,903
		<u>1,319,771</u>	<u>981,403</u>
CREDITORS:	10	(429,652)	(271,557)
Amounts falling due within one year			
NET CURRENT ASSETS		<u>890,119</u>	<u>709,846</u>
NET ASSETS		<u><u>1,407,623</u></u>	<u><u>1,217,203</u></u>
FUNDS:			
Unrestricted funds	12	957,623	767,203
Designated funds	12	450,000	450,000
		<u><u>1,407,623</u></u>	<u><u>1,217,203</u></u>

For the year ended 31 August 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to have an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 6 to 16 were approved and authorised for issue by the officers on and signed on their behalf by:

Martin Rutter

.....
Prof M K Rutter
TRUSTEE

European Diabetology

(A company limited by guarantee)

UNAUDITED STATEMENT OF CASHFLOWS
as at 31 August 2022

	Notes	2022 £	2021 £
Cash generated/(used) by operating activities	14	444,539	(123,544)
Increase/(Decrease) in cash in the year		444,539	(123,544)
Total cash brought forward		<u>874,903</u>	<u>998,447</u>
Total cash carried forward		<u><u>1,319,442</u></u>	<u><u>874,903</u></u>

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2022

1 ACCOUNTING POLICIES

CHARITY INFORMATION

European Diabetology is a private company limited by guarantee and incorporated in England and Wales. The registered office is 2nd Floor, 1 The Square, Temple Quay, Bristol, BS1 6DG.

European Diabetology meets the definition of a public benefit entity under section 34 of FRS 102.

The principal objectives of the charity are detailed in the Trustees report found on page 2 of these financial statements.

The charity is a company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the entity.

ACCOUNTING CONVENTION

The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition – October 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006. The accounting policies as disclosed have been applied consistently throughout the current and preceding year.

The accounts are prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value.

The financial statements presented in sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

GOING CONCERN

The trustees have reviewed the expected cash outflows for the charity against expected cash inflows and assets held for 12 months from the approval of these financial statements. The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these accounts.

FUND ACCOUNTING

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been restricted for other purposes. Designated funds are set aside by the trustees to be spent on specific purposes as its own discretion. The designated funds currently in the financial statements relate to approximately 6 months' running costs of Diabetologia.

INCOME

Income is recognised when the charity is entitled to the income, the value can be measured with sufficient reliability and it is probable the funds will be received.

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

for the year ending 31 August 2022

EXPENDITURE

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Charitable expenditure comprises costs incurred by the charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include independent examination fees and costs linked to the strategic management of the charity.

Grants payable for each year, as agreed by the trustees are included in the accounts of that year.

Commitments to pay grants to specific research projects in future years are conditional on annual reviews of programme and are therefore not provided for until such payments are due. Such commitments are not binding and will be charged against the income of the year in which they are paid.

GAINS AND LOSSES

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the statement of financial activities.

INVESTMENTS

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

FINANCIAL INSTRUMENTS

As the charity only has basic financial instruments it has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102, to all of its financial instruments.

Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

for the year ending 31 August 2022

transaction, where the financial asset is measured at the present value of the future receipts discounted at market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including other payables are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of future payments discounted at a market rate of interest.

TAXATION

The charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

FOREIGN CURRENCIES

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the net income for the year.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2022

2 INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds	Total funds	Total funds
	Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2021 £
Promotion of medical research	625,401	625,401	594,055
	<u>625,401</u>	<u>625,401</u>	<u>594,055</u>
	<u><u>625,401</u></u>	<u><u>625,401</u></u>	<u><u>594,055</u></u>

During the current and prior year all the income from charitable activities was received from markets outside the UK but within Europe.

3 ANALYSIS OF CHARITABLE EXPENDITURE

	Unrestricted funds Activities undertaken directly	Unrestricted funds Support costs (Note 4)	Total funds	Total funds
	Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2021 £
Promotion of medical research	460,062	10,151	470,213	639,525
	<u>460,062</u>	<u>10,151</u>	<u>470,213</u>	<u>639,525</u>
	<u><u>460,062</u></u>	<u><u>10,151</u></u>	<u><u>470,213</u></u>	<u><u>639,525</u></u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2022

4 ALLOCATION OF SUPPORT AND GOVERNANCE COSTS

	Support costs	Governance costs	Total	Total
	Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2021 £
Accountancy costs	8,855	-	8,855	6,718
Bank charges	16	-	16	645
Independent examination fees	-	1,280	1,280	1,620
	<u>8,871</u>	<u>1,280</u>	<u>10,151</u>	<u>8,983</u>

5 RECOGNISED GAINS/(LOSSES)

	Unrestricted funds	Total funds	Total funds
	Year ended 31 August 2022 £	Year ended 31 August 2022 £	Year ended 31 August 2021 £
Unrealised gains/(losses) on investments (note 8)	(8,601)	(8,601)	37,994
	<u>(8,601)</u>	<u>(8,601)</u>	<u>37,994</u>
Foreign exchange gains/(losses)	25,085	25,085	(31,327)
	<u>25,085</u>	<u>25,085</u>	<u>(31,327)</u>

6 TRUSTEES

The Trustees neither received nor waived any emoluments from the charity during the year (2021: £nil). No Trustees received payments (2021: nil) in respect of travel costs reimbursed. The Trustees are considered to be the key management personnel of the charity.

7 EMPLOYEES

European Diabetology has no employees. The personnel are employed by The University of Bristol, who recharge these costs to the charity.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2022

8 INVESTMENTS

	2022 £	2021 £
Valuation at 1 September	507,357	451,903
Additions	18,748	17,460
Unrealised (loss)/gain on investments	(8,601)	37,994
Valuation at 31 August	<u>517,504</u>	<u>507,357</u>

The charity holds investments in a multi-asset fund with Schroders.

9 DEBTORS

	2022 £	2021 £
Prepayments and accrued income	210	106,381
Other debtors	119	119
	<u>329</u>	<u>106,500</u>

10 CREDITORS: Amounts falling due within one year

	2022 £	2021 £
Accruals and deferred income	429,652	271,557
	<u>429,652</u>	<u>271,557</u>

Included in the above is £211,179 (2021: £212,342) of deferred income. This is in relation to the remaining annual amount due from the publishing agreement. All deferred income from 2021 has been released to the statement of financial activities in the current year.

11 FINANCIAL INSTRUMENTS

	2022 £	2021 £
Equity instruments measured at fair value	517,504	507,357
Financial liabilities measured at amortised cost	(218,472)	(59,214)

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2022

12 MOVEMENTS IN FUNDS

	At 1 September 2021	Income	Expenditure	Net gains/ (losses) on investments	Other gains/ (losses) and transfers	At 31 August 2022
	£	£	£	£	£	£
Unrestricted funds	767,203	644,149	(470,213)	(8,601)	25,085	957,623
Designated funds	450,000	-	-	-	-	450,000
	<u>1,217,203</u>	<u>644,149</u>	<u>(470,213)</u>	<u>(8,601)</u>	<u>25,085</u>	<u>1,407,623</u>
	At 1 September 2020	Income	Expenditure	Net gains/ (losses) on investments	Other gains/ (losses) and transfers	At 31 August 2021
	£	£	£	£	£	£
Unrestricted funds	788,545	611,516	(639,525)	37,994	(31,327)	767,203
Designated funds	450,000	-	-	-	-	450,000
	<u>1,238,545</u>	<u>611,516</u>	<u>(639,525)</u>	<u>37,994</u>	<u>(31,327)</u>	<u>1,217,203</u>

No restricted funds were received in the year.

The Trustees have decided to designate approximately 6 months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. The funds remain unrestricted and can be spent at the Trustees' discretion.

13 ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Total Unrestricted Funds	Total Unrestricted Funds
	Year ended 31 August 2022 £	Year ended 31 August 2021 £
Fund balances at 31 August are represented by:		
Fixed assets	517,504	507,357
Current assets	1,319,771	981,403
Creditors: amounts falling due within one year	(429,652)	(271,557)
	<u>1,407,623</u>	<u>1,217,203</u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2022

14 RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASHFLOW FROM OPERATING ACTIVITIES

	2022	2021
	£	£
Net income	190,421	(21,342)
(Loss)/gain on investments	8,601	(37,994)
Dividends from investments	(18,748)	(17,460)
Decrease in debtors	106,171	19,860
Decrease in creditors	158,094	(66,608)
Cash generated /(used) by operating activities	<u>444,539</u>	<u>(123,544)</u>

15 ANALYSIS OF CHANGES IN NET FUNDS

	At 31 August 2021	Cash flows £	At 31 August 2022 £
	£		
Cash at bank and in hand	874,903	444,539	1,319,442
	<u>874,903</u>	<u>444,539</u>	<u>1,319,442</u>

16 RELATED PARTIES

The University of Bristol are the employer of some of the trustees of European Diabetology. Expenses of £192,466 were incurred in relation to the University of Bristol during the year (2021: £627,587). No interest is due if payment is received 30 days from the invoice date. The following balance sheet items relate to amounts due to/ from the University of Bristol.

	2022	2021
	£	£
Prepayments and accrued income	-	106,171
Accruals	211,179	53,086

Accounts

European Diabetology

A COMPANY LIMITED BY GUARANTEE

TRUSTEES' REPORT
AND
UNAUDITED FINANCIAL STATEMENTS

For the year ended

31 August 2021

European Diabetology

(A company limited by guarantee)

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES AND MANAGEMENT COMMITTEE

Prof F Gribble
Prof M Blüher
Prof M K Rutter
Prof K Gillespie
Mrs S Tweddell
Prof B Ahren
Prof E Pearson

COMPANY NUMBER

08652560

REGISTERED CHARITY NUMBER

1156725

REGISTERED OFFICE

Hartwell House
55-61 Victoria Street
Bristol
BS1 6AD

PRINCIPAL OFFICE

Level 3
Learning & Research Building
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB

BANKERS

Barclays Bank Plc
15 Queen Square
Bristol
BS1 4NP

The Trustees present their report and unaudited financial statements for the year ended 31 August 2021.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) second edition – October 2019.

STRUCTURE, GOVERNANCE AND MANAGEMENT

European Diabetology is a company limited by guarantee (Company Registration No 08652560) with charitable status (Charity No 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014.

The Trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof A L Gloyn	(Resigned 30 April 2021)
Prof F Gribble	
Prof M Blüher	
Prof M K Rutter (Chairman)	
Prof K Gillespie	
Mrs S Tweddell	
Prof B Ahren	
Prof E Pearson	(Appointed 1 September 2021)

The day to day management of the charity is carried out by the Trustees, who are appointed by a resolution of the Trustees from a candidate or candidates nominated in writing by the European Association for the Study of Diabetes. The number of Trustees shall not be less than three but shall not be subject to any maximum. The Trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

OBJECTIVES AND ACTIVITIES

The charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results.

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

ACHIEVEMENTS AND PERFORMANCE

The charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal Diabetologia and the website Diapedia, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

European Diabetology
(A company limited by guarantee)
TRUSTEES' REPORT

FINANCIAL REVIEW

Total income for the financial year was £611,516 (2020: £908,487). Outgoings and other gains/losses for the same year were £632,858 (2020: £652,515) creating an annual deficit of £21,342 (2020: surplus £255,972). Total funds carried forward into the new financial year are £1,217,203 (2020: £1,238,545).

INVESTMENT POLICY

During the year, the charity maintained a multi-asset fund with Schroders. As the charity's investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

RESERVES

The Trustees examined the requirements for free reserves in November 2016 and agreed that, given the nature of our work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of 6 months' running costs of Diabetologia to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of Diabetologia as a result of ongoing negotiations and allows the charity to fund Diapedia for a further 12 months if this is the decision of the Trustees based on the review agreed at the meeting of Trustees on 18 November 2019. It also gives adequate working capital to support quality improvement in Diabetologia. The Trustees have decided to earmark these funds to a separate designated fund for clarity within the financial statements. The reserves as of 31 August 2021 are £1,217,203 (2020: £1,238,545).

PLANS FOR FUTURE PERIODS

The charity plans to continue supporting the activities of Diabetologia and to fund quality improvement activities when funds permit.

RISK MANAGEMENT

The Trustees consider the main risk to the future of the charity to be the funding provided, without this the charity would not be able to provide support for the publication of the journal Diabetologia and the website Diapedia. The Trustees have a publishing agreement in place with Springer for this funding and work closely with the funding committee to ensure this future funding is secured.

COVID-19

The Trustees consider the volatility of the global market as a result of the COVID-19 pandemic to be a risk to the investments held by the charity. However, this risk is not expected to materially impact the running of the charity, as investment income is considered a small proportion of overall income for the charity.

SMALL COMPANY PROVISIONS


This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

On behalf of the board of Trustees

Prof M K Rutter

TRUSTEE

Date:



26 Jan 2022

European Diabetology

(A company limited by guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Trustees confirm they have complied with the duty in the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit. When reviewing the aims and objectives of the charitable company and in planning its future activities the Trustees refer to the guidance and consider, in particular, how planned activities will contribute to the aims and objectives they have set.

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report to the Trustees on my examination of the accounts of European Diabetology for the year ended 31 August 2021, which are set out on pages 6 to 16.

Responsibilities and basis of report

As the Trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the accounts present a 'true and fair view' and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

Since the company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

RSM UK Tax and Accounting Limited

KERRY GALLAGHER FCA
The Institute of Chartered Accountants in England and Wales
Chartered Accountant

ON BEHALF OF RSM UK TAX AND ACCOUNTING LIMITED

Chartered Accountants
Davidson House
The Forbury
Reading
RG1 3EU

Date: 31/01/22

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
(including an Income and Expenditure Account)
for the year ended 31 August 2021

		Unrestricted funds	Total funds	Total funds
		Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2020 £
INCOME FROM:				
	Note			
Charitable activities	2	594,055	594,055	891,699
Investments		17,461	17,461	16,788
TOTAL		<u>611,516</u>	<u>611,516</u>	<u>908,487</u>
EXPENDITURE ON:				
Charitable activities	3	(639,525)	(639,525)	(642,386)
TOTAL		<u>(639,525)</u>	<u>(639,525)</u>	<u>(642,386)</u>
Net gains / (losses) on investments	5	37,994	37,994	(1,770)
NET INCOME		<u>9,985</u>	<u>9,985</u>	<u>264,331</u>
Other recognised losses	5	(31,327)	(31,327)	(8,359)
NET MOVEMENT IN FUNDS		<u>(21,342)</u>	<u>(21,342)</u>	<u>255,972</u>
RECONCILIATION OF FUNDS				
Total funds brought forward at 1 September		1,238,545	1,238,545	982,573
TOTAL FUNDS CARRIED FORWARD AT 31 AUGUST		<u>1,217,203</u>	<u>1,217,203</u>	<u>1,238,545</u>

All activities are classed as continuing and were unrestricted in the current and previous year.

European Diabetology
(A company limited by guarantee)

UNAUDITED BALANCE SHEET
as at 31 August 2021

	Note	2021 £	2020 £
FIXED ASSETS			
Investments	8	507,357	451,903
		<u>507,357</u>	<u>451,903</u>
CURRENT ASSETS			
Debtors	9	106,500	126,360
Cash at bank and in hand		874,903	998,447
		<u>981,403</u>	<u>1,124,807</u>
CREDITORS:	10	(271,557)	(338,163)
Amounts falling due within one year			
NET CURRENT ASSETS		<u>709,846</u>	<u>786,642</u>
NET ASSETS		<u><u>1,217,203</u></u>	<u><u>1,238,545</u></u>
FUNDS:			
Unrestricted funds	12	767,203	788,545
Designated funds	12	450,000	450,000
		<u><u>1,217,203</u></u>	<u><u>1,238,545</u></u>


For the year ended 31 August 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to have an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 6 to 16 were approved and authorised for issue by the officers on and signed on their behalf by:

.....
Prof M K Rutter
TRUSTEE


26 Jan 2022

European Diabetology

(A company limited by guarantee)

UNAUDITED STATEMENT OF CASHFLOWS
as at 31 August 2021

	Notes	2021 £	2020 £
Cash generated/(used) by operating activities	14	(123,544)	(154,562)
Decrease in cash in the year		(123,544)	(154,562)
Total cash brought forward		<u>998,447</u>	<u>1,153,009</u>
Total cash carried forward		<u><u>874,903</u></u>	<u><u>998,447</u></u>

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

1 ACCOUNTING POLICIES

CHARITY INFORMATION

European Diabetology is a private company limited by guarantee and incorporated in England and Wales. The registered office is Hartwell House, 55 – 61 Victoria Street, Bristol, BS1 6AD.

European Diabetology meets the definition of a public benefit entity under section 34 of FRS 102.

The principal objectives of the charity are detailed in the Trustees report found on page 2 of these financial statements.

The charity is a company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the entity.

ACCOUNTING CONVENTION

The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition – October 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006. The accounting policies as disclosed have been applied consistently throughout the current and preceding year.

The accounts are prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value.

The financial statements presented in sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

GOING CONCERN

The trustees have reviewed the expected cash outflows for the charity against expected cash inflows and assets held for 12 months from the approval of these financial statements. The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these accounts. In making this assessment the trustees have taken account of the ongoing COVID-19 situation and the associated uncertainties in financial markets.

FUND ACCOUNTING

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been restricted for other purposes. Designated funds are set aside by the trustees to be spent on specific purposes as its own discretion. The designated funds currently in the financial statements relate to approximately 6 months' running costs of Diabetologia.

INCOME

Income is recognised when the charity is entitled to the income, the value can be measured with sufficient reliability and it is probable the funds will be received.

EXPENDITURE

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Charitable expenditure comprises costs incurred by the charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include independent examination fees and costs linked to the strategic management of the charity.

Grants payable for each year, as agreed by the trustees are included in the accounts of that year.

Commitments to pay grants to specific research projects in future years are conditional on annual reviews of programme and are therefore not provided for until such payments are due. Such commitments are not binding and will be charged against the income of the year in which they are paid.

GAINS AND LOSSES

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the statement of financial activities.

INVESTMENTS

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

FINANCIAL INSTRUMENTS

As the charity only has basic financial instruments it has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102, to all of its financial instruments.

Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

transaction, where the financial asset is measured at the present value of the future receipts discounted at market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade and other payables are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of future payments discounted at a market rate of interest.

TAXATION

The charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

FOREIGN CURRENCIES

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the net income for the year.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

2 INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds	Total funds	Total funds
	Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2020 £
Promotion of medical research	594,055	594,055	891,699
	<u>594,055</u>	<u>594,055</u>	<u>891,699</u>
	<u><u>594,055</u></u>	<u><u>594,055</u></u>	<u><u>891,699</u></u>

During the current and prior year all the income from charitable activities was received from markets outside the UK but within Europe.

3 ANALYSIS OF CHARITABLE EXPENDITURE

	Unrestricted funds Activities undertaken directly	Unrestricted funds Support costs (Note 4)	Total funds	Total funds
	Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2020 £
Promotion of medical research	630,542	8,983	639,525	642,386
	<u>630,542</u>	<u>8,983</u>	<u>639,525</u>	<u>642,386</u>
	<u><u>630,542</u></u>	<u><u>8,983</u></u>	<u><u>639,525</u></u>	<u><u>642,386</u></u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

4 ALLOCATION OF SUPPORT AND GOVERNANCE COSTS

	Support costs	Governance costs	Total	Total
	Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2020 £
Travel & subsistence	-	-	-	440
Accountancy costs	6,718	-	6,718	8,143
Bank charges	645	-	645	601
Independent examination fees	-	1,620	1,620	1,400
	<u>7,363</u>	<u>1,620</u>	<u>8,983</u>	<u>10,584</u>

5 RECOGNISED GAINS/(LOSSES)

	Unrestricted funds	Total funds	Total funds
	Year ended 31 August 2021 £	Year ended 31 August 2021 £	Year ended 31 August 2020 £
Unrealised gains/(losses) on investments (note 8)	37,994	37,994	(1,770)
	<u>37,994</u>	<u>37,994</u>	<u>(1,770)</u>
Foreign exchange gains/(losses)	(31,327)	(31,327)	(8,359)
	<u>(31,327)</u>	<u>(31,327)</u>	<u>(8,359)</u>

6 TRUSTEES

The Trustees neither received nor waived any emoluments from the charity during the year (2020: £nil). No Trustees received payments (2020: two Trustees received £440) in respect of travel costs reimbursed. The Trustees are considered to be the key management personnel of the charity.

7 EMPLOYEES

European Diabetology has no employees. The personnel are employed by The University of Bristol, who recharge these costs to the charity.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

8 INVESTMENTS

	2021 £	2020 £
Valuation at 1 September	451,903	436,885
Additions	17,460	16,788
Unrealised gain/(loss) on investments	37,994	(1,770)
Valuation at 31 August	<u>507,357</u>	<u>451,903</u>

The charity holds investments in a multi-asset fund with Schroders.

9 DEBTORS

	2021 £	2020 £
Prepayments and accrued income	106,381	95,998
Other debtors	119	30,362
	<u>106,500</u>	<u>126,360</u>

10 CREDITORS: Amounts falling due within one year

	2021 £	2020 £
Trade creditors	-	71,820
Accruals and deferred income	271,557	266,343
	<u>271,557</u>	<u>338,163</u>

Included in the above is £212,342 (2020: £191,521) of deferred income. This is in relation to the remaining annual amount due from the publishing agreement. All deferred income from 2020 has been released to the statement of financial activities in the current year.

11 FINANCIAL INSTRUMENTS

	2021 £	2020 £
Equity instruments measured at fair value	507,357	451,903
Financial liabilities measured at amortised cost	(59,214)	(146,642)

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

12 MOVEMENTS IN FUNDS

	At 1 September 2020 £	Income £	Expenditure £	Net gains/ (losses) on investments £	Other gains/ (losses) and transfers £	At 31 August 2021 £
Unrestricted funds	788,545	611,516	(639,525)	37,994	(31,327)	767,203
Designated funds	450,000	-	-	-	-	450,000
	<u>1,238,545</u>	<u>611,516</u>	<u>(639,525)</u>	<u>37,994</u>	<u>(31,327)</u>	<u>1,217,203</u>

	At 1 September 2019 £	Income £	Expenditure £	Net gains/ (losses) on investments £	Other gains/ (losses) and transfers £	At 31 August 2020 £
Unrestricted funds	532,573	908,487	(642,386)	(1,770)	(8,359)	788,545
Designated funds	450,000	-	-	-	-	450,000
	<u>982,573</u>	<u>908,487</u>	<u>(642,386)</u>	<u>(1,770)</u>	<u>(8,359)</u>	<u>1,238,545</u>

No restricted funds were received in the year.

The Trustees have decided to designate approximately 6 months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. The funds remain unrestricted and can be spent at the Trustees' discretion.

13 ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Total Unrestricted Funds Year ended 31 August 2021 £	Total Unrestricted Funds Year ended 31 August 2020 £
Fund balances at 31 August are represented by:		
Fixed assets	507,357	451,903
Current assets	981,403	1,124,807
Creditors: amounts falling due within one year	(271,557)	(338,165)
	<u>1,217,203</u>	<u>1,238,545</u>

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2021

14 RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASHFLOW FROM OPERATING ACTIVITIES

	2021	2020
	£	£
Net income	(21,342)	255,972
(Gain)/loss on investments	(37,994)	1,770
Dividends from investments	(17,460)	(16,788)
Decrease in debtors	19,860	8,009
Decrease in creditors	(66,608)	(403,525)
Cash generated /(used) by operating activities	<u>(123,544)</u>	<u>(154,562)</u>

15 ANALYSIS OF CHANGES IN NET FUNDS

	At 31 August 2020	Cash flows	At 31 August 2021
	£	£	£
Cash at bank and in hand	998,447	(123,544)	874,903
	<u>998,447</u>	<u>(123,544)</u>	<u>874,903</u>

16 RELATED PARTIES

The University of Bristol are the employer of some of the trustees of European Diabetology. Expenses of £627,587 were incurred in relation to the University of Bristol during the year (2020: £647,830). No interest is due if payment is received 30 days from the invoice date. The following balance sheet items relate to amounts due to/ from the University of Bristol.

	2021	2020
	£	£
Prepayments and accrued income	106,171	95,760
Trade creditors	-	71,820
Accruals	53,086	69,253

Accounts

European Diabetology

A COMPANY LIMITED BY GUARANTEE

TRUSTEES' REPORT
AND
UNAUDITED FINANCIAL STATEMENTS

For the year ended

31 August 2020

European Diabetology

(A company limited by guarantee)

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES AND MANAGEMENT COMMITTEE

Prof A L Gloyn
Prof F Gribble
Prof M Blüher
Dr M K Rutter
Dr K Gillespie
Mrs S Tweddell
Prof B Ahren

COMPANY NUMBER

08652560

REGISTERED CHARITY NUMBER

1156725

REGISTERED OFFICE

Hartwell House
55-61 Victoria Street
Bristol
BS1 6AD

PRINCIPAL OFFICE

Level 3
Learning & Research Building
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB

BANKERS

Barclays Bank Plc
15 Queen Square
Bristol
BS1 4NP

European Diabetology

(A company limited by guarantee)

TRUSTEES' REPORT

The trustees present their report and unaudited financial statements for the year ended 31 August 2020.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) second edition – October 2019. The accounts have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to give a true and fair view.

STRUCTURE, GOVERNANCE AND MANAGEMENT

European Diabetology is a company limited by guarantee (Company Registration No 08652560) with charitable status (Charity No 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014.

The trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof A L Gloyn	
Prof F Gribble	
Prof M Blüher	
Dr M K Rutter (Chairman)	
Dr K Gillespie	
Mrs S Tweddell	(Appointed 15 November 2019)
Prof B Ahren	(Appointed 17 July 2020)

The day to day management of the charity is carried out by the trustees, who are appointed by a resolution of the trustees from a candidate or candidates nominated in writing by the European Association for the Study of Diabetes. The number of trustees shall not be less than three but shall not be subject to any maximum. The trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

OBJECTIVES AND ACTIVITIES

The charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results.

The trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

ACHIEVEMENTS AND PERFORMANCE

The charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal Diabetologia and the website Diapedia, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

FINANCIAL REVIEW

Total income for the financial year was £908,487 (2019: £843,089). Outgoings and other gains/losses for the same year were £652,515 (2019: £677,287) creating an annual surplus of £255,972 (2019: £165,802). Total funds carried forward into the new financial year are £1,238,545 (2019: £982,573).

European Diabetology
(A company limited by guarantee)
TRUSTEES' REPORT

INVESTMENT POLICY

During the year, the charity maintained a multi-asset fund with Schroders. As the charity's investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

RESERVES

The trustees examined the requirements for free reserves in November 2016 and agreed that, given the nature of our work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of 6 months' running costs of Diabetologia to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of Diabetologia as a result of ongoing negotiations and allows the charity to fund Diapedia for a further 12 months if this is the decision of the trustees based on the review agreed at the meeting of trustees on April 11th 2014. It also gives adequate working capital to support quality improvement in Diabetologia. The trustees have decided to earmark these funds to a separate designated fund for clarity within the financial statements. The reserves as of 31 August 2020 are £1,238,545 (2019: £982,573).

PLANS FOR FUTURE PERIODS

The charity plans to continue supporting the activities of Diabetologia and to fund quality improvement activities when funds permit.

RISK MANAGEMENT

The trustees consider the main risk to the future of the charity to be the funding provided, without this the charity would not be able to provide support for the publication of the journal Diabetologia and the website Diapedia. The trustees have a publishing agreement in place with Springer for this funding and work closely with the funding committee to ensure this future funding is secured.


COVID-19

The Trustees consider the volatility of the global market as a result of the COVID-19 pandemic to be a risk to the investments held by the charity. However, this risk is not expected to materially impact the running of the charity, as investment income is considered a small proportion of overall income for the charity.

SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

On behalf of the board of Trustees



Dr M K Rutter

TRUSTEE

Date: 1/2/21

European Diabetology

(A company limited by guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The trustees confirm they have complied with the duty in the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit. When reviewing the aims and objectives of the charitable company and in planning its future activities the trustees refer to the guidance and consider, in particular, how planned activities will contribute to the aims and objectives they have set.

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report to the trustees on my examination of the accounts of European Diabetology for the year ended 31 August 2020, which are set out on pages 6 to 16.

Responsibilities and basis of report

As the trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the accounts present a 'true and fair view' and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

Since the company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Frances Millar

FRANCES MILLAR ACA
The Institute of Chartered Accountants in England and Wales
Chartered Accountant

ON BEHALF OF RSM UK TAX AND ACCOUNTING LIMITED

Chartered Accountants
Highfield Court
Tollgate
Chandlers Ford
Eastleigh
SO53 3TY

Date: 3 February 2021

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
(including an Income and Expenditure Account)
for the year ended 31 August 2020

		Unrestricted funds	Total funds	Total funds
		Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2019 £
INCOME FROM:				
	Note			
Charitable activities	2	891,699	891,699	827,010
Investments		16,788	16,788	16,079
TOTAL		<u>908,487</u>	<u>908,487</u>	<u>843,089</u>
EXPENDITURE ON:				
Charitable activities	3	(642,386)	(642,386)	(678,510)
TOTAL		<u>(642,386)</u>	<u>(642,386)</u>	<u>(678,510)</u>
Net gains / (losses) on investments	5	(1,770)	(1,770)	(8,113)
NET INCOME		<u>264,331</u>	<u>264,331</u>	<u>156,466</u>
Other recognised gains	5	(8,359)	(8,359)	9,336
NET MOVEMENT IN FUNDS		<u>255,972</u>	<u>255,972</u>	<u>165,802</u>
RECONCILIATION OF FUNDS				
Total funds brought forward at 1 September		982,573	982,573	816,771
TOTAL FUNDS CARRIED FORWARD AT 31 AUGUST		<u><u>1,238,545</u></u>	<u><u>1,238,545</u></u>	<u><u>982,573</u></u>

All activities are classed as continuing and were unrestricted in the current and previous year.

European Diabetology

(A company limited by guarantee)

UNAUDITED BALANCE SHEET

as at 31 August 2020


	Note	2020 £	2019 £
FIXED ASSETS			
Investments	8	451,903	436,885
		<u>451,903</u>	<u>436,885</u>
CURRENT ASSETS			
Debtors	9	126,360	134,369
Cash at bank and in hand		998,447	1,153,009
		<u>1,124,807</u>	<u>1,287,378</u>
CREDITORS:	10	(338,165)	(741,690)
Amounts falling due within one year			
NET CURRENT ASSETS		<u>786,642</u>	<u>545,688</u>
NET ASSETS		<u><u>1,238,545</u></u>	<u><u>982,573</u></u>
FUNDS:			
Unrestricted funds	12	788,545	532,573
Designated funds	12	450,000	450,000
		<u><u>1,238,545</u></u>	<u><u>982,573</u></u>

For the year ended 31 August 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to have an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 6 to 16 were approved and authorised for issue by the officers on and signed on their behalf by:



 Dr M K Rutter
 TRUSTEE

1/2/21

European Diabetology

(A company limited by guarantee)

UNAUDITED STATEMENT OF CASHFLOWS
as at 31 August 2020

	Notes	2020 £	2019 £
Cash generated /(used) by operating activities	14	(154,562)	557,241
Cash flows from investing activities			
Dividends from investments		-	-
Total cash flows from investing activities		-	-
Increase in cash in the year		(154,562)	557,241
Total cash brought forward		<u>1,153,009</u>	<u>595,768</u>
Total cash carried forward		<u><u>998,447</u></u>	<u><u>1,153,009</u></u>

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

1 ACCOUNTING POLICIES

CHARITY INFORMATION

European Diabetology is a private company limited by guarantee and incorporated in England and Wales. The registered office is Hartwell House, 55 – 61 Victoria Street, Bristol, BS1 6AD.

European Diabetology meets the definition of a public benefit entity under section 34 of FRS 102.

The principal objectives of the charity are detailed in the Trustees report found on page 2 of these financial statements.

The charity is a company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the entity.

ACCOUNTING CONVENTION

The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition – October 2019 issued on 16 July 2014 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Practice as it applies from 1 January 2019. The accounting policies as disclosed have been applied consistently throughout the current and preceding year.

The charity has adopted the Charities SORP (FRS 102) issued in October 2019 rather than applying the Charities 2005 SORP which has been withdrawn but is still referred to in the extant Charities (Accounts and Reports) Regulations 2008. This departure has been necessary for the financial statements to show a true and fair view in accordance with United Kingdom Generally Accepted Accounting Practice effective for accounting periods beginning on or after 1 January 2015.

The accounts are prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value.

The financial statements presented in sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

GOING CONCERN

The trustees have reviewed the expected cash outflows for the charity against expected cash inflows and assets held for 12 months from the approval of these financial statements. The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these accounts. In making this assessment the trustees have taken account of the ongoing COVID-19 situation and the associated uncertainties in financial markets.

FUND ACCOUNTING

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been restricted for other purposes. Designated funds are set aside by the trustees to be spent on specific purposes as its own discretion. The designated funds currently in the financial statements relate to approximately 6 months' running costs of Diabetologia.

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

INCOME

Incoming resources are recognised as incoming resources when the charity is entitled to the income, the value can be measured with sufficient reliability and it is probable the funds will be received.

EXPENDITURE

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Charitable expenditure comprises costs incurred by the charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include independent examination fees and costs linked to the strategic management of the charity.

Grants payable for each year, as agreed by the trustees are included in the accounts of that year.

Commitments to pay grants to specific research projects in future years are conditional on annual reviews of programme and are therefore not provided for until such payments are due. Such commitments are not binding and will be charged against the income of the year in which they are paid.

GAINS AND LOSSES

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the statement of financial activities.

INVESTMENTS

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

FINANCIAL INSTRUMENTS

As the charity only has basic financial instruments it has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102, to all of its financial instruments.

Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

FINANCIAL INSTRUMENTS (*continued*)

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing

transaction, where the financial asset is measured at the present value of the future receipts discounted at market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade and other payables are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of future payments discounted at a market rate of interest.

TAXATION

The charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

FOREIGN CURRENCIES

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the net income for the year.

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

2 INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds	Total funds	Total funds
	Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2019 £
Promotion of medical research	891,699	891,699	827,010
	<u>891,699</u>	<u>891,699</u>	<u>827,010</u>
	=====	=====	=====

During the current and prior year all the income from charitable activities was required from markets outside the UK but within Europe.

3 ANALYSIS OF CHARITABLE EXPENDITURE

	Unrestricted funds Activities undertaken directly	Unrestricted funds Support costs (Note 4)	Total funds	Total funds
	Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2019 £
Promotion of medical research	631,802	10,584	642,386	678,510
	<u>631,802</u>	<u>10,584</u>	<u>642,386</u>	<u>678,510</u>
	=====	=====	=====	=====

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

4 ALLOCATION OF SUPPORT AND GOVERNANCE COSTS

	Support costs	Governance costs	Total	Total
	Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2019 £
Travel & subsistence	440	-	440	1,372
Accountancy costs	8,143	-	8,143	7,625
Bank charges	601	-	601	697
Independent examination fees	-	1,400	1,400	1,400
	<u>9,184</u>	<u>1,400</u>	<u>10,584</u>	<u>11,094</u>

5 RECOGNISED GAINS/(LOSSES)

	Unrestricted funds	Total funds	Total funds
	Year ended 31 August 2020 £	Year ended 31 August 2020 £	Year ended 31 August 2019 £
Unrealised gains/(losses) on investments (note 8)	(1,770)	(1,770)	(8,113)
	<u>(1,770)</u>	<u>(1,770)</u>	<u>(8,113)</u>
Foreign exchange gains/(losses)	(8,359)	(8,359)	9,336
	<u>(8,359)</u>	<u>(8,359)</u>	<u>9,336</u>

6 TRUSTEES

The trustees neither received nor waived any emoluments from the charity during the year (2019: £nil). Two trustees received payments totalling £440 (2019: four trustees received £928) in respect of travel costs reimbursed. The trustees are considered to be the key management personnel of the charity.

7 EMPLOYEES

European Diabetology has no employees. The personnel are employed by The University of Bristol, who recharge these costs to the charity.

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

8 INVESTMENTS

	2020 £	2019 £
Valuation at 1 September	436,885	428,919
Additions	16,788	16,079
Unrealised gain/(loss) on investments	(1,770)	(8,113)
Valuation at 31 August	<u>451,903</u>	<u>436,885</u>

The charity holds investments in a multi-asset fund with Schroders.

9 DEBTORS

	2020 £	2019 £
Prepayments and accrued income	95,998	102,910
Other debtors	30,362	31,459
	<u>126,360</u>	<u>134,369</u>

10 CREDITORS: Amounts falling due within one year

	2020 £	2019 £
Trade creditors	71,820	463,612
Accruals and deferred income	266,343	278,078
	<u>338,163</u>	<u>741,690</u>

Included in the above is £191,521 (2019: £205,497) of deferred income. This is in relation to the remaining annual amount due from the publishing agreement. All deferred income from 2019 has been released to the statement of financial activities in the current year.

11 FINANCIAL INSTRUMENTS

	2020 £	2019 £
Equity instruments measured at fair value	451,903	436,885
Financial liabilities measured at amortised cost	(146,642)	(536,193)

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

12 MOVEMENTS IN FUNDS

	At 1 September 2019 £	Income £	Expenditure £	Net gains (losses) on investments £	Other gains/ (losses) and transfers £	At 31 August 2020 £
Unrestricted funds	532,573	908,487	(642,386)	(1,770)	(8,359)	788,545
Designated funds	450,000	-	-	-	-	450,000
	<u>982,573</u>	<u>908,487</u>	<u>(642,386)</u>	<u>(1,770)</u>	<u>(8,359)</u>	<u>1,238,545</u>

	At 1 September 2018 £	Income £	Expenditure £	Net gains (losses) on investments £	Other gains/ (losses) and transfers £	At 31 August 2019 £
Unrestricted funds	366,771	843,089	(678,510)	(8,113)	9,336	532,573
Designated funds	450,000	-	-	-	-	450,000
	<u>816,771</u>	<u>843,089</u>	<u>(678,510)</u>	<u>(8,113)</u>	<u>9,336</u>	<u>982,573</u>

No restricted funds were received in the year.

The trustees have decided to designate approximately 6 months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer. The funds remain unrestricted and can be spent at the trustees' discretion.

13 ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Total Unrestricted Funds Year ended 31 August 2020 £	Total Unrestricted Funds Year ended 31 August 2019 £
Fund balances at 31 August are represented by:		
Fixed assets	451,903	436,885
Current assets	1,124,807	1,287,378
Creditors: amounts falling due within one year	(338,165)	(741,690)
	<u>1,238,545</u>	<u>982,573</u>

European Diabetology

(A company limited by guarantee)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS (continued)
for the year ending 31 August 2020

14 RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASHFLOW FROM OPERATING ACTIVITIES

	2020	2019
	£	£
Net income	255,972	165,802
Loss/(gain) on investments	1,770	8,113
Dividends from investments	(16,788)	(16,079)
(Increase)/decrease in debtors	8,009	(2,300)
Increase/(decrease) in creditors	(403,525)	401,705
Cash generated /(used) by operating activities	<u>(154,562)</u>	<u>557,241</u>

15 ANALYSIS OF CHANGES IN NET FUNDS

	At 1 September 2019 £	Cash flows £	At 31 August 2020 £
Cash at bank and in hand	1,153,009	(154,562)	998,447
	<u>1,153,009</u>	<u>(154,562)</u>	<u>998,447</u>

16 RELATED PARTIES

The University of Bristol are the employer of some of the trustees of European Diabetology. Expenses of £647,830 were incurred in relation to the University of Bristol during the year (2019: £615,033). No interest is due if payment is received 30 days from the invoice date. The following balance sheet items relate to amounts due to/ from the University of Bristol.

	2020 £	2019 £
Prepayments and accrued income	95,760	102,749
Trade creditors	71,820	462,908
Accruals	69,253	51,374